source
- Manufacturing hurdles grow as next-gen protein therapeutics gain tractionCytiva's sponsored piece highlights growing interest in next-generation protein-based drugs such as antibody-drug conjugates, multispecific antibodies, fragments and synthetic peptides. These moda…
- Aspen Neuroscience and Bambusa Therapeutics each aim for $135 million IPOsAspen Neuroscience announced plans to raise about $135 million through an initial public offering, proposing to sell roughly 9.38 million shares. Bambusa Therapeutics also filed for an IPO targeti…